Aperiam Bio
Biotechnology company using computational methods to stabilize recombinant protein structures, solving a ubiquitous problem in industrial biotechnology.
Website
https://www.aperiambio.comLocation
Seattle, Washington, USA
Founded
2020
Investors
1
Categories
biotech, protein-engineering, computational-biology, industrial-biotech
Notes
Aperiam Bio uses advanced computational methods to stabilize recombinant protein structures, addressing one of the most challenging problems in industrial biotechnology. The company's approach enables the production of more stable proteins for various applications including therapeutics, enzymes, and industrial processes.
The technology builds on foundational work in computational protein design, enabling rapid identification of stabilizing mutations that improve protein expression, stability, and manufacturability.
Team
- David Baker, Ph.D. - Scientific Co-founder (University of Washington, Institute for Protein Design)
- Lukasz Jaroszewski, Ph.D. - Co-founder & CEO
Additional Research Findings
- Computational protein stabilization platform
- Technology from University of Washington / Institute for Protein Design
- Applications in therapeutics, industrial enzymes, and biotech
- Improving protein expression and stability
- AI/ML-enabled protein engineering
- Based in Seattle near academic collaborators
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |